Evidence map›Paper›PMID 39037588›Full record

ArticleAnnals of hematology2024

Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis.

Keiki Nagaharu, Eiko Ohya, Yoko Edahiro, Yoshinori Hashimoto, Tomoki Ito, Akihiko Gotoh, Mika Nakamae, Fumihiko Kimura, Michiaki Koike, Keita Kirito and 18 more

Erratum issuedAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Keiki NagaharuDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Mie Prefecture, Japan. keiki-nagaharu@med.mie-u.ac.jp.
Eiko OhyaDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Mie Prefecture, Japan.
Yoko EdahiroDepartment of Hematology, Juntendo University Graduate School of Medicine, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Yoshinori HashimotoDepartment of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan.
Tomoki ItoFirst Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Akihiko GotohDepartment of Hematology, Tokyo Medical University, Tokyo, Japan.
Mika NakamaeDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Fumihiko KimuraDivision of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan.
Michiaki KoikeDepartment of Hematology, Juntendo University Shizuoka Hospital, Shizuoka, Japan.
Keita KiritoDepartment of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan.
Hideho WadaDepartment of Hematology, Kawasaki Medical School, Okayama, Japan.
Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
Takayuki TanakaDepartment of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan.
Takehiko MoriDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Satoshi WakitaDivision of Hematology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Toshiki I SaitoClinical Research Center, NHO Nagoya Medical Center, Aichi, Japan.
Akiko M SaitoClinical Research Center, NHO Nagoya Medical Center, Aichi, Japan.
Kazuya ShimodaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Toshiro KurokawaDepartment of Hematology, Toyama Red Cross Hospital, Toyama, Japan.
Akihiro TomitaDepartment of Hematology, Fujita Health University School of Medicine, Aichi, Japan.
Hitoshi KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Aichi, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Itaru MatsumuraDivision of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan.
Katsuto TakenakaDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan.
Norio KomatsuDepartment of Hematology, Juntendo University Graduate School of Medicine, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Kohshi OhishiDepartment of Transfusion Medicine and Cell Therapy, Mie University Hospital, Mie Prefecture, Japan.
Isao TawaraDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Mie Prefecture, Japan.
Yuka SugimotoDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Mie Prefecture, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombosis in myeloproliferative neoplasms (MPNs) is an important clinical problem, and risk-stratified management is essential. To identify the clinical characteristics of thrombosis in patients with MPNs, a nationwide multi-institutional retrospective analysis (JSH-MPN-R18) was conducted. The aim of the present study was to perform a sub-analysis of JSH-MPN-R18 findings to clarify the predictive parameters for thrombosis among complete blood count (CBC) results. Among the patients enrolled in JSH-MPN-R18, those with essential thrombocythemia (ET; n = 1152) and polycythemia vera (PV; n = 456) were investigated. We analyzed and compared CBC parameters between patients with and those without any thrombotic events using Welch's T-test. Statistical analyses were performed using the R statistical software. Thrombotic events were observed in 74 patients with ET. In multivariate analysis, only the neutrophil ratio was slightly but significantly higher for ET patients with thrombosis than for those without (p < 0.05). Of note, the absolute neutrophil count (aNeu) was considered a useful predictive tool for thrombosis among patients classified as low-risk according to the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia. Among PV patients, those with thrombosis showed significantly higher hematocrit and aNeu than did those without thrombosis. As a thrombosis-associated factor, the neutrophil ratio was slightly but significantly elevated in patients with ET. This myeloid skew might reflect a higher value of JAK2 V617F allelic frequency in patients with ET with thrombosis; this was not clarified in JSH-MPN-R18. Further accumulation of evidence, including genetic information for JAK2 and other passenger mutations, is warranted.

Indexed as

Janus Kinase 2NeutrophilsPolycythemia VeraThrombocythemia, EssentialThrombosisAdultAgedAged, 80 and overFemaleHumansLeukocyte CountMaleMiddle AgedMyeloproliferative DisordersPredictive Value of TestsRetrospective StudiesJAK2 protein, humanJanus Kinase 2Essential thrombosisJAK2 mutationPolycythemia veraThrombosis

Identifiers

PMID39037588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.